← Browse by Condition
Medical Condition

melanoma

Total Trials
28
Recruiting Now
28
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2
NCT05867004
Recruiting

Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma

Enrollment
100 pts
Location
France
Sponsor
Institut Claudius Regaud
View Trial →
NCT06418204
Recruiting

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Enrollment
2,000 pts
Location
United States, Puert...
Sponsor
Wake Forest University Health ...
View Trial →
NCT06272864
Recruiting

BostonGene and Exigent Genomic INsight Study

Enrollment
400 pts
Location
United States
Sponsor
BostonGene
View Trial →
NCT05770544 Phase 2, Phase 3
Recruiting

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
View Trial →
NCT07092670
Recruiting

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Enrollment
270 pts
Location
Italy
Sponsor
Intergruppo Melanoma Italiano
View Trial →
NCT07260591 Phase 1
Recruiting

VSV-02 Compassionate Use in Advanced Solid Tumors

Enrollment
6 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT06229340 Phase 2
Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Enrollment
20 pts
Location
Russia
Sponsor
N.N. Petrov National Medical R...
View Trial →
NCT05334069
Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Enrollment
2,000 pts
Location
United States
Sponsor
Alliance for Clinical Trials i...
View Trial →
NCT04386967 Phase 1, Phase 2
Recruiting

OH2 Injection in Solid Tumors

Enrollment
30 pts
Location
China
Sponsor
Binhui Biopharmaceutical Co., ...
View Trial →
NCT06047379 Phase 1, Phase 2
Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Enrollment
134 pts
Location
United States
Sponsor
Neonc Technologies, Inc.
View Trial →
NCT05076760 Phase 1
Recruiting

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Enrollment
40 pts
Location
United States
Sponsor
Memgen, Inc.
View Trial →
NCT04572451 Phase 1
Recruiting

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Enrollment
50 pts
Location
United States
Sponsor
Yana Najjar
View Trial →
NCT04729543 Phase 1, Phase 2
Recruiting

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

Enrollment
20 pts
Location
Netherlands
Sponsor
Erasmus Medical Center
View Trial →
NCT02870244 Phase 1
Recruiting

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Enrollment
18 pts
Location
United States
Sponsor
Loyola University
View Trial →
NCT01772771
Recruiting

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

Enrollment
12,000 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT05522660 Phase 3
Recruiting

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

Enrollment
180 pts
Location
Italy, Netherlands, ...
Sponsor
ETOP IBCSG Partners Foundation
View Trial →
NCT06887348
Recruiting

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Enrollment
50 pts
Location
United States, Austr...
Sponsor
Replimune Inc.
View Trial →
NCT07161310
Recruiting

Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors

Enrollment
45 pts
Location
Germany
Sponsor
Goethe University
View Trial →
NCT03787056
Recruiting

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Enrollment
410 pts
Location
France
Sponsor
Hospices Civils de Lyon
View Trial →
NCT06666634
Recruiting

Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy

Enrollment
29 pts
Location
Netherlands
Sponsor
The Netherlands Cancer Institu...
View Trial →
NCT05899465 Phase 3
Recruiting

Perioperative Treatment With Tranexamic Acid in Melanoma

Enrollment
1,204 pts
Location
Denmark
Sponsor
University of Aarhus
View Trial →
NCT04193956
Recruiting

POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors

Enrollment
3,500 pts
Location
Netherlands
Sponsor
University Medical Center Gron...
View Trial →
NCT05483400 Phase 2
Recruiting

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

Enrollment
97 pts
Location
Netherlands
Sponsor
University Medical Center Gron...
View Trial →
NCT04616443 Phase 1, Phase 2
Recruiting

OH2 Injection in Combination With HX008 for Melanoma.

Enrollment
60 pts
Location
China
Sponsor
Binhui Biopharmaceutical Co., ...
View Trial →
NCT05768178 Phase 2, Phase 3
Recruiting

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Enrollment
30 pts
Location
United Kingdom
Sponsor
Cancer Research UK
View Trial →
NCT06281678 Phase 2
Recruiting

A Study of IBI363 in Subjects with Advanced Solid Malignancies

Enrollment
178 pts
Location
United States
Sponsor
Innovent Biologics (Suzhou) Co...
View Trial →
NCT05264974 Phase 1
Recruiting

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

Enrollment
18 pts
Location
United States
Sponsor
University of Florida
View Trial →
NCT07042243
Recruiting

The Florida ASCENT Study

Enrollment
100 pts
Location
United States
Sponsor
University of Florida
View Trial →